Eagle Pharmaceuticals Investor Relations Material
Latest events
Q2 2023
Eagle Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Eagle Pharmaceuticals Inc
Access all reports
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. It primarily offers Ryanodex, an intravenous formulation of dantrolene sodium used for treating patients in various malignant hyperthermia crises. The company also develops Bendeka, a once-daily intravenous formulation of bendamustine hydrochloride that is in late-stage development for the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma.
Key slides for Eagle Pharmaceuticals Inc
Corporate Presentation
Eagle Pharmaceuticals Inc
Corporate Presentation
Eagle Pharmaceuticals Inc
Latest articles
Sundar Pichai: CEO of Alphabet and Google
Explore Sundar Pichai's improbable journey from Chennai, India, to becoming one of the most powerful individuals on the planet.
19 Apr 2024
The Three Cornerstones of Serial Acquirer Success
Explore what is behind successful serial acquirers: efficient capital use, decentralization, and a strong focus on people.
19 Apr 2024
Companies That Had Their IPO in 2023: Cautious Optimism
The cautiously optimistic market in 2023 saw stocks rebounded upwards, and interest in IPOs picked up from the previous year.
15 Apr 2024
Ticker symbol
Country
🇺🇸 United States